

# 1 **Impact of Hormonal Contraceptives on HPV Dynamics in Adolescent Girls and Young** 2 **Women: Insights from a Randomized Controlled Sub-Study in South Africa**

3 Ramla F. Tanko<sup>1,2\*</sup>, Ongeziwe Taku<sup>1</sup>, Zizipho Z. A. Mbulawa<sup>1,3,4</sup>, Keletso Phohlo<sup>1</sup>, Iyaloo Konstantinus<sup>1,10</sup>, Christina  
4 Balle<sup>1</sup>, Tanya Pidwell<sup>1</sup>, Anna-Ursula Happel<sup>1,5</sup>, Katherine Gill,<sup>1,6</sup> Linda-Gail Bekker<sup>1,6</sup>, Heather B. Jaspan<sup>1,7#</sup>, Anna-Lise  
5 Williamson<sup>1#</sup>, Jo-Ann S. Passmore<sup>1,8,9#</sup>

6 <sup>1</sup>Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, South Africa; <sup>2</sup>The Medical  
7 Research Centre, Institute of Medical Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and  
8 Innovation, Yaoundé, Cameroon; <sup>3</sup>Department of Laboratory Medicine and Pathology, Walter Sisulu University,  
9 Mthatha, Eastern Cape, South Africa; <sup>4</sup>National Health Laboratory Service, Mthatha, South Africa; <sup>5</sup>Division of  
10 Immunology, University of Cape Town, South Africa; <sup>6</sup>Desmond Tutu Health Foundation, Cape Town, South Africa;  
11 <sup>7</sup>Seattle Children's Research Institute, Seattle, USA; <sup>8</sup>Department of Science and Technology-National Research  
12 Foundation CAPRISA Centre of Excellence in HIV Prevention, Cape Town, South Africa; <sup>9</sup>National Health Laboratory  
13 Service, Cape Town, South Africa, <sup>10</sup>Namibia Institute of Pathology, Windhoek, Namibia

14

15 **#Co-last authors**

16 **Correspondence:** Professor Jo-Ann Passmore, Institute of Infectious Disease and Molecular Medicine, Division of  
17 Medical Virology, University of Cape Town, Werner Beit North, Level 3 South Pavilion N3.2; Anzio Road, Observatory,  
18 7925, Cape Town, South Africa.

19 Phone: +27 21 650 7963, e-mail: [jo-ann.passmore@uct.ac.za](mailto:jo-ann.passmore@uct.ac.za)

20 **Keywords:** Human papillomavirus, HPV, adolescents, persistence, contraceptives, Net-EN, COCPs, CCVR

21 Words: 1676

22 Figures: 2

23 Tables: 2

24 Supplementary Figure: 1

25 Running title: Hormonal contraceptives and HPV dynamics in adolescents

26 **ABSTRACT (234 words)**

27 Objectives: Human papillomavirus (HPV) is the leading cause of cervical cancer, with adolescent  
28 girls and young women (AGYW) in sub-Saharan Africa carrying a disproportionately high burden of  
29 infection. Hormonal contraceptives may influence HPV acquisition, persistence, and clearance, but  
30 evidence remains inconclusive. This sub-study aimed to evaluate the impact of different hormonal  
31 contraceptives on HPV prevalence and genotype distribution in AGYW.

32 Methods: Ninety-eight HIV-seronegative AGYW aged 15–19 years from South Africa were  
33 randomized to receive one of three hormonal contraceptive methods: norethisterone enanthate (Net-  
34 EN) injectable, combined oral contraceptive pills (COCPs), or the etonorgesterol/ethinyl estradiol  
35 combined contraceptive vaginal ring (CCVR). Cervical DNA samples were collected at baseline and  
36 after 16 weeks for HPV genotyping using the HPV Direct Flow Chip test. HPV prevalence,  
37 persistence, clearance, and acquisition were analyzed across contraceptive methods.

38 Results: At baseline, HPV prevalence was high (94.9%), with no differences among contraceptive  
39 arms. After 16 weeks, HPV prevalence remained high (89.5%) across groups. No significant  
40 differences were observed in overall HPV prevalence or genotype distribution by contraceptive  
41 method. Longitudinal analysis revealed that AGYW using Net-EN tended to have a higher  
42 cumulative number of high-risk HPV (HR-HPV) genotypes that cleared whereas those using CCVR  
43 acquired more HR-HPV types and had greater HR-HPV persistence compared to other groups.

44 Conclusions: This study highlights the high burden of HPV among South African AGYW. However,  
45 different hormonal contraceptive methods did not significantly influence HR-HPV dynamics.

46

47

## 48 INTRODUCTION

49 Human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections (STIs)  
50 affecting the human genital tract (1). Of the over 200 identified HPV types, only certain mucosal  
51 types are classified as high-risk (HR) due to their strong association with cancers (2,3). HPV-16 and  
52 HPV-18 are responsible for ~70% of cervical cancer cases globally and contribute significantly to  
53 other HPV-related malignancies, including anal, vaginal, vulvar, penile, and oropharyngeal cancers.  
54 Cervical cancer remains particularly widespread in sub-Saharan Africa, where incidence rates surpass  
55 those of other regions (4,5).

56 Risk of HPV infection is likely to be influenced by a combination of environmental, biological, and  
57 behavioral factors. Biologically, an impaired immune system, such as in individuals with HIV/AIDS,  
58 increases susceptibility to persistent HPV infections, while genetic predispositions (6) and co-  
59 infections with other STIs further elevate the risk (7). Key behavioral factors include early sexual  
60 debut, unprotected sex, multiple sexual partners, smoking, and prolonged use of hormonal  
61 contraceptives—all of which are associated with heightened risks of infection and cervical cancer (8).  
62 Understanding these complex factors is essential for developing targeted prevention and intervention  
63 strategies.

64 Observational studies have suggested that hormonal contraceptives may influence HPV dynamics (9-  
65 11). For instance, combined oral contraceptive pills (COCPs) have been associated with reduced  
66 HPV clearance, though other studies found no effect except with extended exposure. Meta-analyses  
67 suggest prolonged hormonal contraceptive use is linked to invasive cervical cancer (12,13), yet  
68 evidence on its relationship with HPV detection remains inconclusive.

69 Adolescent girls and young women (AGYW) in South Africa carry a high burden of HPV infection  
70 (14). Many of these AGYW are within their first year of sexual debut, with a median of one lifetime

71 sexual partner (15), underscoring the alarming overlap between high HPV prevalence and vaccine  
72 coverage gaps.

73 This study investigated HPV prevalence and genotype distribution at baseline and after 16 weeks of  
74 hormonal contraceptive use in AGYW randomized to receive norethisterone enanthate (Net-EN),  
75 etonorgesterol/ethinyl estradiol combined contraceptive vaginal ring (CCVR), or COCPs.  
76 Importantly, data on HPV infection and CCVR use are limited. Understanding the impact of  
77 hormonal contraceptives on HPV dynamics is critical for guiding effective vaccination and  
78 reproductive health strategies.

79

## 80 **METHODS AND MATERIALS**

### 81 **Description of study cohort**

82 Between September 2015 and July 2017, 130 AGYW between the ages of 15 and 19 were recruited  
83 from the Desmond Tutu Health Foundation Youth Centre in Cape Town into an open-label,  
84 randomized crossover study evaluating the acceptability, feasibility, and adherence to contraceptive  
85 choices (uChoose study; clinicaltrials.gov number NCT02404038) (15). Eligible participants were  
86 HIV-seronegative, sexually active, not pregnant, had no symptomatic STIs that required antibiotic  
87 treatment in the 40 days prior to enrolment, and agreed not to use non-study vaginal products for the  
88 duration of the study. Following screening (baseline visit), eligible AGYW were randomized 1:1:1 to  
89 receive one of three hormonal contraceptives: NET-EN (200 mg), COCPs (Triphasil® or Nordette®;  
90 both containing ethinyl estradiol and levonorgestrel), or CCVR (Nuvaring®; etonogestrel/ethinyl  
91 estradiol) for 16 weeks. AGYW who were <18 years provided written assent, and informed consent  
92 was obtained from their parents or legal guardians. AGYW who were  $\geq 18$  years old provided written

93 informed consent. Ethical approval for the study was obtained from the University of Cape Town  
94 Human Research Ethics Committees (UCT HREC 801/2014).

95

#### 96 **Testing for bacterial STIs and Bacterial vaginosis (BV)**

97 At the time of sampling, vulvovaginal swabs were screened for *Chlamydia trachomatis*, *Neisseria*  
98 *gonorrhoea*, *Trichomonas vaginalis*, and *Mycoplasma genitalium* using a real-time multiplex PCR  
99 (16). BV was diagnosed using Nugent scoring, with Nugent Scores of 7-10 indicating a BV positive  
100 result (17). Vaginal pH levels were measured using color-fixed indicator strips (Macherey-Nagel,  
101 Düren, Germany). Participants who tested positive for STIs and/or BV received treatment according  
102 to the South African National guidelines.

103

#### 104 **HPV genotyping**

105 HPV genotyping was performed at baseline and after 16 weeks on extracted DNA (MagNA Pure  
106 Compact Nucleic Acid Isolation Kit; Roche), from endocervical swabs collected during the speculum  
107 examination, using the HPV Direct Flow Chip test (Master Diagnostica, Granada, Spain), according  
108 to the manufacturers' instructions. The Direct Flow Chip detects 36 different HPV genotypes,  
109 including the 12 HR types according to the International Agency for Research on Cancer (IARC) (3)  
110 (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59), an additional 5 HPV types previously considered  
111 HR (26, 53, 66, 73, 82; according to the kit manufacturers), and 18 low-risk (LR) types (6, 11, 40, 42,  
112 43, 44, 54, 55, 61, 62, 67, 69, 70, 71, 72, 81, 84, 89). For the purposes of HR-HPV analysis, the  
113 recent IARC (3) definition of HR-HPV types was used. For the purposes of LR-HPV analysis, the  
114 manufacturers definition of LR-HPV types was used. A sample was considered HPV positive when  
115 at least one HPV genotype was detected. Specimens testing positive for 2 or more HPV genotypes  
116 were considered to have multiple infections. Acquiring a new HPV infection was defined as detection  
117 of any HPV type at 16 weeks in AGYW who did not have that HPV type present at baseline. HPV

118 persistence was defined as having the same HPV genotype detected at both baseline and 16 weeks, in  
119 the same participant. HPV clearance was defined as women testing negative for any HPV genotype at  
120 16 weeks that was present at baseline.

121

## 122 **Statistical analyses**

123 Fisher's exact test and descriptive statistics were used to compare differences between hormonal  
124 contraceptive arms for categorical variables. Continuous variables were described using median and  
125 interquartile range (IQR) and compared using the Kruskal Wallis-test.  $P < 0.05$  was considered  
126 statistically significant. Statistical analyses were performed using GraphPad Prism version 9  
127 (GraphPad Software, USA).

128

## 129 **RESULTS**

130 Of the 130 AGYW enrolled into the parent uChoose study, endocervical samples were available for  
131 HPV genotyping from 98 women at baseline (74.5%) and 95 at 16 weeks (73.1%; **Supplementary**  
132 **Figure 1**). This included 36 matched sample pairs (baseline and 16 weeks) from adolescents  
133 randomized to receive Net-EN, 25 matched samples from AGYW randomized to receive COCPs, and  
134 26 who were randomized to receive the CCVR.

135

136 Demographics, genital infections, sexual risk behaviors, prior hormonal contraceptive use, and  
137 endogenous hormone levels did not significantly differ among hormonal contraceptive methods at  
138 baseline (**Table 1**). At baseline, HPV prevalence was high, with an overall prevalence of 94.9%  
139 (93/98), which did not differ between randomization arms (**Figure 1 and Table 2**). Most (80.5%)  
140 AGYW had multiple infections with HPV. Baseline prevalence of any HR-HPV was 78.9%. HPV-16  
141 and HPV-18 were detected in 6/98 (6.1%) and 14/98 (14.2%) AGYW, respectively, with HPV-31

142 and HPV-39 being the most commonly detected HR type (both 18/98; 18.4%) (**Figure 2A**). While  
143 South Africa initiated the Cervarix (HPV-16/18) vaccination program a year before recruitment for  
144 uChoose began (19), which targeted grade 4 learners (aged 9 years or older), the AGYW enrolled in  
145 this study were unlikely to have been vaccinated as no catch-up vaccines were offered. The 9-valent  
146 Merck HPV vaccine would improve coverage although this does not contain other common HR-HPV  
147 types found in this cohort (HPV-39, HPV-56 [16/98; %], HPV-59 [14/98; 14.2%]; **Figure 2A**).

148

149 At 16 weeks, the HPV prevalence remained high (89.5%). Overall HPV prevalence and HR-HPV  
150 prevalence did not differ significantly by study arm (**Figure 1 and Table 2**). AGYW randomized to  
151 the Net-EN arm had an HPV prevalence (any) of 86.1% at 16 weeks compared to 97.2% at baseline  
152 (31/36 vs 35/36,  $p=0.2$ ), those using COCPs had the same HPV prevalence at baseline and 16 weeks  
153 (both 88.0% [22/25];  $p=1.0$ ), and those randomized to the CCVR group had an HPV prevalence of  
154 96.2% at 16 weeks compared to 92.3% at baseline (25/26 vs 24/26;  $p=1.0$ ). For HR-HPV types,  
155 66.7% of women randomized to Net-EN had a HR-HPV type at 16 weeks compared to 80.6% at  
156 baseline (24/36 vs 29/36,  $p=0.3$ ), 56.0% of those using COCPs had HR-HPV infections at week 16  
157 compared to 72.0% at baseline (14/25 vs 18/25;  $p=0.4$ ), and those randomized to the CCVR group  
158 had an HPV prevalence of 76.9% at 16 weeks compared to 80.8% at baseline (20/26 vs 21/26;  
159  $p=1.0$ ).

160

161 Longitudinal analyses of HR-HPV genotype distribution showed no significant differences between  
162 the hormonal contraceptive arms, whether considering women who cleared infections (by type), had  
163 persistent infections (same type), or acquired new HPV genotype infections (by type; **Figure 2B**).  
164 However, there tended to be higher combined prevalence of new HR-HPV types acquired and that  
165 persisted in the CCVR arm compared to the other contraceptives arms. In contrast, adolescents in the

166 Net-EN arm tended to have higher combined prevalence of HR-HPV counts cleared during the study  
167 than the other two arms.

168

## 169 **DISCUSSION**

170 This sub-study of a randomized controlled trial (15) compared HPV prevalence and genotype  
171 distribution among AGYW randomized to three common hormonal contraceptives: CCVR, the  
172 injectable Net-EN, and COCPs. Our results revealed high HPV prevalence across all contraceptive  
173 methods at baseline, with no significant differences in overall prevalence or genotype distribution  
174 linked to any specific contraceptive arm after 16 weeks of use. Longitudinal analyses showed some  
175 variations in HR-HPV dynamics over the 16-week study period, although these were not significant.  
176 AGYW using Net-EN tended to clear more HR-HPV types, whereas those using the CCVR tended to  
177 acquire more HR-HPV infections that persisted compared to those in the other contraceptive arms.

178

179 The high HPV prevalence observed in this cohort aligns with other studies indicating that AGYW are  
180 at significant risk of acquiring HPV infections shortly after sexual debut (20,21). This rapid increase,  
181 often within the first six months of sexual activity, is influenced by factors such as sexual behaviors,  
182 the number of sexual partners, and immune response (22). In this study, an early average age of  
183 sexual debut (13 years) and additional risk factors, such as inconsistent condom use (43.9%),  
184 multiple sexual partners (21.4%), and high rates of other STIs (e.g., *C. trachomatis* prevalence of  
185 31.6%), likely contributed to the high HPV rates at baseline.

186

187 We have previously shown that hormonal contraceptives exert distinct effects on the mucosal  
188 environment of the female genital tract, as evidenced by changes in microbial composition (23),  
189 inflammatory markers (24), and gene expression (25). In this cohort, adolescents randomized to Net-  
190 EN exhibited higher vaginal microbial diversity and proinflammatory taxa compared to those using



191 COCPs, who had associated with increased lactobacilli and reduced genital inflammation (23,24).  
192 CCVR use, however, was linked to elevated transcriptional networks involving interleukin (IL)-6,  
193 IL-1, and NF- $\kappa$ B, suggesting increased genital tract inflammation, alongside reduced epithelial  
194 barrier integrity (25). As altered vaginal microbiota (26), reduced genital barrier integrity (27) and  
195 chronic inflammation (28) have all previously been associated with increased risk for HPV infection  
196 and carcinogenesis, this may explain our observation that AGYW using the CCVR might be more  
197 likely to acquire and retain HR-HPV infections compared to other contraceptive users.

198

199 The findings suggest that hormonal contraceptives may differentially impact HR-HPV acquisition,  
200 persistence, and clearance. The observed benefits of Net-EN in clearing HR-HPV types and the  
201 increased acquisition and persistence associated with CCVR underscore the need to explore  
202 biological mechanisms underlying these effects. These insights are critical for tailoring contraceptive  
203 counseling and HPV prevention strategies, particularly in high-risk populations like AGYW in sub-  
204 Saharan Africa. Further research is essential to validate these findings and assess the long-term  
205 implications for cervical health and cancer prevention.

206 **1. ACKNOWLEDGMENTS**

207 We are grateful to all the uChoose study participants and protocol team: Ms Penelope Ngcobo for  
208 recruiting and consenting participants, Dr Eve Mendel the study clinician, Sister Janine Nixon the  
209 study nurse and Ms Keshani Naidoo for processing the samples, Ms Maria Mwakatima and Zoe  
210 Baker for editorial and review support.

211 **2. AUTHOR CONTRIBUTIONS**

212 Conceived and designed the experiments: J.A.P, R.F.T., H.J., A.L.W. Designed and recruited the  
213 study participants: L.G.B., K.G., T.P., and S.B. Processed samples: I.K., C.B., S.J., A.H., and H.G.  
214 Performed the experiments: T.F.M., K.P., O.T., and Z.Z.A.M. Analysed the data: R.F.T., and J.A.P.  
215 Wrote the manuscript: All authors.

216

217 **FUNDING**

218 This work was funded by the South African Medical Research Council and the US National Institute  
219 of Health (R01 HD083040 for this sub-study to [PIs: Heather Jaspan and Jo-Ann Passmore], and  
220 R01AI094586 for the parent study to Linda Gail-Bekker. Merck donated the CCVRs for the study.

221 This HPV sub-study was funded by a grant from the Poliomyelitis Research Foundation to Dr  
222 Passmore, and a grant from NRF SARChi Chair to Prof Anna-Lise Williamson.

223

224 **CONFLICT OF INTEREST**

225 All authors declare no potential conflict of interest.

### 226 3. REFERENCES

- 227 1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global  
228 estimates of the prevalence and incidence of four curable sexually transmitted infections in  
229 2012 based on systematic review and global reporting. *PloS one*. 2015;10(12):e0143304.
- 230 2. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus  
231 Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current  
232 Perspectives. *J Oncol*. 2019 Oct 10;2019:3257939. doi: 10.1155/2019/3257939. PMID:  
233 31687023; PMCID: PMC6811952.
- 234 3. Wei F, Georges D, Man I, Baussano I, Clifford GM (2024). Causal attribution of human  
235 papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the  
236 global literature. *Lancet*. Published online 1 August 2024; [https://doi.org/10.1016/S0140-  
237 6736\(24\)01097-3](https://doi.org/10.1016/S0140-6736(24)01097-3).
- 238 4. Jedy-Agba E, Joko WY, Liu B, Buziba NG, Borok M, Korir A, Masamba L, Manraj SS,  
239 Finesse A, Wabinga H, Somdyala N, Parkin DM. Trends in cervical cancer incidence in sub-  
240 Saharan Africa. *Br J Cancer*. 2020 Jul;123(1):148-154. doi: 10.1038/s41416-020-0831-9.  
241 Epub 2020 Apr 27. PMID: 32336751; PMCID: PMC7341858.
- 242 5. Ramogola-Masire D, Luckett R, Dreyer G. Progress and challenges in human papillomavirus  
243 and cervical cancer in southern Africa. *Current Opinion in Infectious Diseases*.  
244 2022;35(1):49-54.
- 245 6. Adebamowo, S. N., et al. (2024). Genome, HLA and polygenic risk score analyses for  
246 prevalent and persistent cervical human papillomavirus (HPV) infections. *European Journal  
247 of Human Genetics*. doi.org/10.1038/s41431-023-01521-7.
- 248 7. Hewavisenti RV, Arena J, Ahlenstiel CL, Sasson SC. Human papillomavirus in the setting of  
249 immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce  
250 the high associated cancer risk. *Front Immunol*. 2023 Mar 7;14:1112513. doi:  
251 10.3389/fimmu.2023.1112513. PMID: 36960048; PMCID: PMC10027931.
- 252 8. Pino M, Vorsters A, Joura EA, et al. Risk factors for human papillomavirus infection and  
253 disease: a targeted literature summary. *J Med Virol*. 2024; 96:e29420. doi:10.1002/jmv.29420
- 254 9. Marks M, Gravitt PE, Gupta SB, Liaw K-L, Tadesse A, Kim E, et al. Combined oral  
255 contraceptive use increases HPV persistence but not new HPV detection in a cohort of  
256 women from Thailand. *Journal of Infectious Diseases*. 2011;204(10):1505-13.
- 257 10. Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A, et al. The association of  
258 hormonal contraceptive use and HPV prevalence. *International journal of cancer*.  
259 2011;128(12):2962-70.
- 260 11. Chong G, Bo Z, Meng-Yuan L, Li Y, Chao Z. Association between oral contraceptives and  
261 cervical cancer: A retrospective case–control study based on the National Health and  
262 Nutrition Examination Survey. *Frontiers in Pharmacology*. 2024. 15.  
263 DOI=10.3389/fphar.2024.1400667
- 264 12. Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer-A  
265 systematic review & meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2020 Apr;247:163-  
266 175. doi: 10.1016/j.ejogrb.2020.02.014. Epub 2020 Feb 21. PMID: 32114321.
- 267 13. Damayanti, S., Budihastuti, U. R., & Murti, B. (2023). Meta-Analysis: Effects of Hormonal  
268 Contraceptive Use and History of Sexually Transmitted Disease on the Risk of Cervical  
269 Cancer. *Journal of Maternal and Child Health*, 8(6), 711–722.  
270 <https://doi.org/10.26911/thejmch.2023.08.06.05>
- 271 14. Mbulawa ZZA, van Schalkwyk C, Hu NC, Meiring TL, Barnabas S, Dabee S, Jaspan H,  
272 Kriek JM, Jaumdally SZ, Muller E, Bekker LG, Lewis DA, Dietrich J, Gray G, Passmore JS,  
273 Williamson AL. High human papillomavirus (HPV) prevalence in South African adolescents

- 274 and young women encourages expanded HPV vaccination campaigns. *PLoS One*. 2018 Jan  
275 2;13(1):e0190166. doi: 10.1371/journal.pone.0190166. PMID: 29293566; PMCID:  
276 PMC5749739.
- 277 15. Gill, K., Happel, A.U., Pidwell, T., Mendelsohn, A., Duyver, M., Johnson, L., Meyer, L., Slac  
278 k, C., Strode, A., Mendel, E., Fynn, L., Wallace, M., Spiegel, H., Jaspan, H., Passmore, J.-  
279 A., Hosek, S., Smit, D., Rinehart, A. and Bekker, L.-G. An open-label, randomized crossover  
280 study to evaluate the acceptability and preference for contraceptive options in female  
281 adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods  
282 (UChoose). *J Int AIDS Soc* 2020; 23(10):e25626
- 283 16. Lewis DA, Müller E, Steele L, Sternberg M, Radebe F, Lyall M, et al. Prevalence and  
284 associations of genital ulcer and urethral pathogens in men presenting with genital ulcer  
285 syndrome to primary health care clinics in South Africa. *Sexually transmitted diseases*.  
286 2012;880-5.
- 287 17. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved  
288 by a standardized method of gram stain interpretation. *Journal of clinical microbiology*.  
289 1991;29(2):297-301.
- 290 18. Herraiez-Hernandez E, Alvarez-Perez M, Navarro-Bustos G, Esquivias J, Alonso S, Aneiros-  
291 Fernandez J, et al. HPV Direct Flow CHIP: A new human papillomavirus genotyping method  
292 based on direct PCR from crude-cell extracts. *Journal of virological methods*. 2013;193(1):9-  
293 17.
- 294 19. Delany-Moretlwe, S., Kelley, K.F., James, S., Scorgie, F., Subedar, H., Dlamini, N.R., Pillay,  
295 Y., Naidoo, N., Chikandiwa, A. and Rees, H., 2018. Human papillomavirus vaccine  
296 introduction in South Africa: implementation lessons from an evaluation of the national  
297 school-based vaccination campaign. *Global Health: Science and Practice*, 6(3), pp.425-438.
- 298 20. Houlihan CF, de Sanjosé S, Baisley K, Changalucha J, Ross DA, Kapiga S, et al. Prevalence  
299 of human papillomavirus in adolescent girls before reported sexual debut. *The Journal of*  
300 *infectious diseases*. 2014;210(6):837-45.
- 301 21. Smith JS. Prevalence of human papillomavirus infection in adolescent girls before reported  
302 sexual debut. Oxford University Press; 2014. p. 835-6.
- 303 22. Marks MA, Klein SL, Gravitt PE. Hormonal contraception and HPV: a tale of differing and  
304 overlapping mechanisms. *Open Access Journal of Contraception*. 2011:161-74.
- 305 23. Balle, C., Konstantinus, I.N., Jaumdally, S.Z. *et al.* Hormonal contraception alters vaginal  
306 microbiota and cytokines in South African adolescents in a randomized trial. *Nat*  
307 *Commun* 11, 5578 (2020). <https://doi.org/10.1038/s41467-020-19382-9>.
- 308 24. Konstantinus IN, Balle C, Jaumdally SZ, Galmiendien H, Pidwell T, Masson L, Tanko RF,  
309 Happel AU, Sinkala M, Myer L, Bosinger SE, Gill K, Bekker LG, Jaspan HB, Passmore JS.  
310 Impact of Hormonal Contraceptives on Cervical T-helper 17 Phenotype and Function in  
311 Adolescents: Results from a Randomized, Crossover Study Comparing Long-acting  
312 Injectable Norethisterone Oenanthate (NET-EN), Combined Oral Contraceptive Pills, and  
313 Combined Contraceptive Vaginal Rings. *Clin Infect Dis*. 2020 Oct 23;71(7):e76-e87. doi:  
314 10.1093/cid/ciz1063. PMID: 31675420; PMCID: PMC7755094.
- 315 25. Balle C, Gupta PM, Tharp GK, Nelson SA, Konstantinus I, Lennard K, Jaumdally SZ, Happel  
316 AU, Barnabas SL, Gill K, Bekker LG, Passmore JS, Jaspan HB, Bosinger SE. Systems  
317 Analysis Reveals Contraceptive-Induced Alteration of Cervicovaginal Gene Expression in a  
318 Randomized Trial. *Frontiers in Reproductive Health*, 2022. 4,  
319 DOI=10.3389/frph.2022.781687
- 320 26. Lin, W., Zhang, Q., Chen, Y. *et al.* Changes of the vaginal microbiota in HPV infection and  
321 cervical intraepithelial neoplasia: a cross-sectional analysis. *Sci Rep* 12, 2812 (2022).  
322 <https://doi.org/10.1038/s41598-022-06731-5>

- 323 27. Qulu W, Mtshali A, Osman F, Ndlela N, Ntuli L, Mzobe G, Naicker N, Garrett N, Rompalo  
324 A, Mindel A, Ngcapu S, Liebenberg L. High-risk human papillomavirus prevalence among  
325 South African women diagnosed with other STIs and BV. *PLoS One*. 2023 Nov  
326 30;18(11):e0294698. doi: 10.1371/journal.pone.0294698. PMID: 38032961; PMCID:  
327 PMC10688634.
- 328 28. Fernandes JV, DE Medeiros Fernandes TA, DE Azevedo JC, Cobucci RN, DE Carvalho MG,  
329 Andrade VS, DE Araújo JM. Link between chronic inflammation and human papillomavirus-  
330 induced carcinogenesis. *Oncol Lett*. 2015 Mar;9(3):1015-1026. doi: 10.3892/ol.2015.2884.  
331 Epub 2015 Jan 16. PMID: 25663851; PMCID: PMC4315066.

332 **Table 1.** Baseline characteristics of AGYW in UChoose HPV sub-study

Contraceptive arm	All	Net-EN <sup>a</sup>	COCP	CCVR <sup>b</sup>	333
n	98/130 (75.4%)	44/98 (44.9%)	24/98 (24.5%)	25/98 (25.5%)	334
Age (years)*	17.0 (16.0 – 18.0)	17.0 (16.0 – 18.0)	16.0 (16.0 – 18.0)	17.0 (16.0 – 18.0)	335
Body mass index (kg/m <sup>2</sup> )*	25.1 (21.5 – 29.1)	25.8 (22.6 – 29.8)	25.5 (20.7 – 30.5)	24.9 (21.1 – 28.8)	336
Age of sexual debut (years)*	13 (12.0 – 14.0)	13 (12.0 – 14.0)	14 (12.0 – 15.0)	13 (12.0 – 14.0)	337
Condom use during last sex	55/98 (56.1%)	24/44 (54.5%)	14/24 (58.3%)	15/25 (60.0%)	338
>1 sex partners in past year	21/98 (21.4%)	10 (27.8%)	5 (20.8%)	6 (24.0%)	339
New partners in past year	28/98 (28.6%)	10 (22.7%)	7 (29.2%)	10 (40.0%)	340
Prior hormonal contraceptive use:					341
Never	1/98 (1.0%)	1 (2.3%)	0 (0.0%)	0 (0.0%)	342
Not currently	21/98 (21.4%)	9 (20.5%)	7 (29.2%)	4 (16.0%)	343
DMPA	9/98 (9.2%)	4 (9.1%)	4 (16.7%)	1 (4.0%)	344
Implanon	2/98 (2.0%)	1(2.3%)	0 (0.0%)	1 (4.0%)	345
COCPs	3/98 (3.1%)	2 (4.5%)	0 (0.0%)	1 (4.0%)	346
Net-EN	62/98 (63.3%)	27 (61.4%)	13 (54.2%)	18 (72.0%)	347
Vaginal pH*	4.9 (4.4 – 5.3)	5.0 (4.7 – 5.3)	4.7 (4.4 – 5.0)	4.7 (4.4 – 5.3)	348
Bacterial vaginosis:					349
Negative (Nugent 0 – 3)	46/98 (46.9%)	18/44 (40.9%)	12/24 (50.0%)	13/25 (52.0%)	350
Intermediate (Nugent 4 – 6)	10/98 (10.2%)	6/44 (13.6%)	1/24 (4.2%)	2/25 (8.0%)	351
Positive (Nugent 7 – 10)	42/98 (42.9%)	20/44 (45.5%)	10/24 (41.7%)	11/25 (44.0%)	352
STIs:					353
<i>Chlamydia trachomatis</i>	31/98 (31.6%)	12/44 (27.3%)	9/24 (37.5%)	9/25 (36.0%)	354
<i>Neisseria gonorrhoeae</i>	12/98 (12.2%)	5/44 (11.4%)	3/24 (12.5%)	3/25 (12.0%)	355
<i>Trachomatis vaginalis</i>	8/98 (8.2%)	5/44 (11.4%)	1/24 (4.2%)	2/25 (8.0%)	356
<i>Mycoplasma genitalium</i>	3/98 (3.1%)	2/44 (4.6%)	1/24 (4.2%)	0/25 (0.0%)	357

373 : sample size  
 374 <sup>a</sup>No record available for age of sexual debut (n=3), condom use during last sex (n=8), numbers of sexual partners (n=8), new partners (n=9) and  
 375 endogenous hormone levels (n=2) and n=1  
 376 <sup>b</sup>No data available for endogenous hormone levels (n=1)  
 377

378 **Table 2.** HPV prevalence at baseline and 16 week visits for paired samples

HPV types	Baseline			16 weeks		
	Net-EN	COCP	CCVR	Net-EN	COCP	CCVR
Any HPV	35/36 (97.2%)	22/25 (88.0%)	25/26 (96.2%)	31/36 (86.1%)	22/25 (88.0%)	24/26 (92.3%)
HR-HPV	29/36 (80.60%)	18/25 (72.0%)	21/26 (80.8%)	24/36 (66.7%)	14/25 (56.0%)	20/26 (76.9%)
LR-HPV	27/36 (75.0%)	22/25 (88.0%)	21/26 (80.8%)	23/36 (63.9%)	18/25 (72.0%)	16/26 (61.5%)
Multiple HPV	27/36 (75.0%)	20/25 (80.0%)	19/26 (73.1%)	21/36 (58.3%)	16/25 (64.0%)	19/26 (73.1%)

380 **Figure 1. Dynamics of HPV Infections Across Contraceptive Methods.**

381 This figure illustrates the percentage of AGYW with cleared, persistent, and newly acquired HPV  
382 infections, based on paired data between baseline and week 16 visits. Results are stratified by  
383 hormonal contraceptive methods: CCVR (n=26), COCPs (n=25), and Net-EN (n=36). Color coding  
384 reflects infection categories: pink for any HPV, orange for HR HPV, darker blue for LR-HPV, and  
385 lighter blue for multiple HPVs.

386 **Figure 2. HPV Genotype Distribution Across Contraceptive Arms.**

387 (A) Distribution of HPV genotypes among AGYW at baseline and 16 weeks. Each bar graph  
388 represents the prevalence of a specific HPV genotype. Light colors indicate low-risk HPV (LR-HPV)  
389 types, while dark colors represent HR-HPV types. Genotypes no longer considered by IARC (3) to  
390 be HR are shown in green italics. Genotypes targeted by the bivalent (HPV 16, 18), quadrivalent  
391 (HPV 6, 11, 16, 18), and nonavalent (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccines are highlighted  
392 in bold. (B) Stacked bars show the prevalence of HR HPV types (including HPV-66 and -68 which  
393 were previously classified as HR) that were newly acquired between 0 and 16 weeks (left panel),  
394 cleared (middle panel), or persisted (right panel), stratified by genotype and contraceptive method.  
395 Panels represent data for Net-EN (n=36), COCPs (n=25), and CCVR (n=26), based on paired  
396 samples between baseline and week 16 visits.

397 **Supplemental Figure 1. Study design overview**

398 Study design for the open-label, randomized crossover trial conducted among adolescent girls and  
399 young women (AGYW). Participants were randomized to one of three hormonal contraceptive  
400 methods: combined oral contraceptive pills (COCPs), injectable Net-EN, or combined contraceptive  
401 vaginal ring (CCVR). Each participant used their assigned contraceptive method for 16 weeks before  
402 crossing over to another method, with no washout period between interventions. The primary



403 outcomes were acceptability, feasibility, and adherence. Assessments were conducted at baseline, and  
404 16 weeks. The crossover design allowed each participant to serve as their own control, enabling  
405 robust comparisons between the different contraceptive methods.






Figure 1




Figure 2A





Figure 2B



Supplemental Figure 1